HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT06000501

Serdexmethylphenidate/dexmethylphenidate for ADHD

It tested serdexmethylphenidate/dexmethylphenidate for ADHD.

ADHDDrugFrom 18 Years to 60 Years
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 60 years.

Listed locations
New York, United StatesSee all locations and recruitment

Compensation and expense reimbursement have not been verified for this summary.

Study clarity

Study information

Study start dateStarted: November 13, 2023
Recruitment status
Completed
Enrollment listed in the registry
29
Sponsor
NYU Langone Health
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
From 18 Years to 60 Years
Official registry ID
NCT06000501
Official title
An Open-Label Treatment, Investigator-Initiated Study, on the Duration and Efficacy of Azstarys (Serdexmethylphenidate and Dexmethylphenidate) on Adult ADHD Symptoms and Executive Function in Early Evening

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

New York

Checked Official study record (opens in a new tab)
FAQ

Questions about this study

Who is behind this study?

The study sponsor is NYU Langone Health.

Did this study involve medication?

Yes. The study involved medication, including Serdexmethylphenidate/dexmethylphenidate.

Who was this study for?

Listed age limits: 18 years to 60 years.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me
Related studies

Explore related studies

Other studies that may be relevant based on condition, country, or study type.